Featured Publications
Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials
Oikonomou EK, Spatz ES, Suchard MA, Khera R. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials. The Lancet Digital Health 2022, 4: e796-e805. PMID: 36307193, PMCID: PMC9768739, DOI: 10.1016/s2589-7500(22)00170-4.Peer-Reviewed Original ResearchConceptsSystolic blood pressure controlBlood pressure controlIntensive systolic blood pressure controlType 2 diabetesPressure controlCardiovascular benefitsClinical trialsMajor adverse cardiovascular eventsFirst major adverse cardiovascular eventLarge randomised clinical trialsACCORD-BP trialAdverse cardiovascular eventsRandomised clinical trialsSystolic blood pressureCox regression analysisTreatment effectsHazard ratio estimatesACCORD-BPBP trialCardiovascular eventsBlood pressurePrimary outcomeStandard treatmentBaseline variablesIndex patientsExamining the potential role of e-cigarettes to reduce health disparities associated with menthol cigarette use: Characterizing e-cigarette use, flavors, and reasons for use among US adults smoking menthol cigarettes
Bold KW, Buta E, Simon P, Gueorguieva R, Jackson A, Suttiratana SC, Krishnan-Sarin S, O'Malley SS. Examining the potential role of e-cigarettes to reduce health disparities associated with menthol cigarette use: Characterizing e-cigarette use, flavors, and reasons for use among US adults smoking menthol cigarettes. Drug And Alcohol Dependence 2022, 236: 109475. PMID: 35594642, PMCID: PMC9248755, DOI: 10.1016/j.drugalcdep.2022.109475.Peer-Reviewed Original ResearchElectronic Alerts to Improve Heart Failure Therapy in Outpatient Practice A Cluster Randomized Trial
Ghazi L, Yamamoto Y, Riello RJ, Coronel-Moreno C, Martin M, O'Connor KD, Simonov M, Huang J, Olufade T, McDermott J, Dhar R, Inzucchi SE, Velazquez EJ, Wilson FP, Desai NR, Ahmad T. Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice A Cluster Randomized Trial. Journal Of The American College Of Cardiology 2022, 79: 2203-2213. PMID: 35385798, DOI: 10.1016/j.jacc.2022.03.338.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyUsual careEjection fractionHeart failureMedical therapyPrimary outcomeCluster-randomized comparative effectiveness trialSodium-glucose cotransporter 2 inhibitorsElectronic health record alertsAldosterone system inhibitorsReduced ejection fractionUsual care armCotransporter 2 inhibitorsMineralocorticoid receptor antagonistsVentricular ejection fractionComparative effectiveness trialNumber of patientsKnowledge of guidelinesLow-cost interventionCare armDays postrandomizationEligible patientsGDMT useFailure therapyPatient characteristicsSingle-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19
Unterman A, Sumida TS, Nouri N, Yan X, Zhao AY, Gasque V, Schupp JC, Asashima H, Liu Y, Cosme C, Deng W, Chen M, Raredon MSB, Hoehn KB, Wang G, Wang Z, DeIuliis G, Ravindra NG, Li N, Castaldi C, Wong P, Fournier J, Bermejo S, Sharma L, Casanovas-Massana A, Vogels CBF, Wyllie AL, Grubaugh ND, Melillo A, Meng H, Stein Y, Minasyan M, Mohanty S, Ruff WE, Cohen I, Raddassi K, Niklason L, Ko A, Montgomery R, Farhadian S, Iwasaki A, Shaw A, van Dijk D, Zhao H, Kleinstein S, Hafler D, Kaminski N, Dela Cruz C. Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19. Nature Communications 2022, 13: 440. PMID: 35064122, PMCID: PMC8782894, DOI: 10.1038/s41467-021-27716-4.Peer-Reviewed Original ResearchMeSH KeywordsAdaptive ImmunityAgedAntibodies, Monoclonal, HumanizedCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCells, CulturedCOVID-19COVID-19 Drug TreatmentFemaleGene Expression ProfilingGene Expression RegulationHumansImmunity, InnateMaleReceptors, Antigen, B-CellReceptors, Antigen, T-CellRNA-SeqSARS-CoV-2Single-Cell AnalysisConceptsProgressive COVID-19B cell clonesSingle-cell analysisT cellsImmune responseMulti-omics single-cell analysisCOVID-19Cell clonesAdaptive immune interactionsSevere COVID-19Dynamic immune responsesGene expressionSARS-CoV-2 virusAdaptive immune systemSomatic hypermutation frequenciesCellular effectsProtein markersEffector CD8Immune signaturesProgressive diseaseHypermutation frequencyProgressive courseClassical monocytesClonesImmune interactionsAssessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients With and Without COVID-19
Nugent J, Aklilu A, Yamamoto Y, Simonov M, Li F, Biswas A, Ghazi L, Greenberg J, Mansour S, Moledina D, Wilson FP. Assessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients With and Without COVID-19. JAMA Network Open 2021, 4: e211095. PMID: 33688965, PMCID: PMC7948062, DOI: 10.1001/jamanetworkopen.2021.1095.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedAged, 80 and overBlack or African AmericanCohort StudiesComorbidityCOVID-19CreatinineFemaleFollow-Up StudiesGlomerular Filtration RateHispanic or LatinoHumansHypertensionKidney Function TestsLongitudinal StudiesMaleMiddle AgedPatient DischargeProportional Hazards ModelsRenal Insufficiency, ChronicRetrospective StudiesSARS-CoV-2United StatesConceptsCOVID-19-associated acute kidney injuryAcute kidney injuryHospital acute kidney injurySubgroup of patientsKidney functionKidney injuryCohort studyHospital dischargeAKI recoveryKidney diseaseCOVID-19Peak creatinine levelsRetrospective cohort studyChronic kidney diseaseDays of dischargeHalf of patientsGlomerular filtration rateCoronavirus disease 2019AKI severityBaseline comorbiditiesEGFR decreaseDialysis requirementEGFR slopeKidney recoveryCreatinine levelsThe Association of COVID-19 With Acute Kidney Injury Independent of Severity of Illness: A Multicenter Cohort Study
Moledina DG, Simonov M, Yamamoto Y, Alausa J, Arora T, Biswas A, Cantley LG, Ghazi L, Greenberg JH, Hinchcliff M, Huang C, Mansour SG, Martin M, Peixoto A, Schulz W, Subair L, Testani JM, Ugwuowo U, Young P, Wilson FP. The Association of COVID-19 With Acute Kidney Injury Independent of Severity of Illness: A Multicenter Cohort Study. American Journal Of Kidney Diseases 2021, 77: 490-499.e1. PMID: 33422598, PMCID: PMC7791318, DOI: 10.1053/j.ajkd.2020.12.007.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedC-Reactive ProteinCohort StudiesCOVID-19CreatinineDiureticsFemaleHospital MortalityHumansIntensive Care UnitsLength of StayMaleMiddle AgedProportional Hazards ModelsRenal DialysisRenal Insufficiency, ChronicRespiration, ArtificialRisk FactorsSARS-CoV-2Severity of Illness IndexUnited StatesVasoconstrictor AgentsConceptsAcute kidney injurySARS-CoV-2Cohort studyRisk factorsCOVID-19Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testingTime-updated Cox proportional hazards modelsDialysis-requiring acute kidney injuryYale New Haven Health SystemHigher inflammatory marker levelsMore acute kidney injuryCox proportional hazards modelMulticenter cohort studyHigh rateInflammatory marker levelsTraditional risk factorsProportional hazards modelCoronavirus disease 2019KDIGO criteriaNephrotoxin exposureKidney injuryInjury independentUnivariable analysisNasopharyngeal samplesMarker levelsReproducible Genetic Risk Loci for Anxiety: Results From ∼200,000 Participants in the Million Veteran Program
Levey DF, Gelernter J, Polimanti R, Zhou H, Cheng Z, Aslan M, Quaden R, Concato J, Radhakrishnan K, Bryois J, Sullivan PF, Stein M. Reproducible Genetic Risk Loci for Anxiety: Results From ∼200,000 Participants in the Million Veteran Program. American Journal Of Psychiatry 2020, 177: 223-232. PMID: 31906708, PMCID: PMC7869502, DOI: 10.1176/appi.ajp.2019.19030256.Peer-Reviewed Original ResearchConceptsNovel genome-wide significant associationsGene expressionGenome-wide significant signalsGenome-wide significant associationMillion Veteran ProgramWide association studyGenetic risk lociSignificant genetic correlationsGenetic risk mechanismsGenetic architectureGlobal regulatorChromosome 3Risk lociChromosome 6Chromosome 7Association studiesLargest GWASLarge biobanksGlobal regulationGenetic correlationsContinuous traitsVeteran ProgramGWASsLociPrevious GWASsGenome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations
Kranzler HR, Zhou H, Kember RL, Vickers Smith R, Justice AC, Damrauer S, Tsao PS, Klarin D, Baras A, Reid J, Overton J, Rader DJ, Cheng Z, Tate JP, Becker WC, Concato J, Xu K, Polimanti R, Zhao H, Gelernter J. Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. Nature Communications 2019, 10: 1499. PMID: 30940813, PMCID: PMC6445072, DOI: 10.1038/s41467-019-09480-8.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesAssociation studiesMillion Veteran Program sampleGenetic correlationsWide significant lociSignificant genetic correlationsPolygenic risk scoresCell type groupSignificant lociHeritable traitEnrichment analysisTraitsMultiple populationsLociPhenotypeProgram samplesGenomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO
Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Özduman K, Avşar T, Li J, Murray PB, Henegariu O, Yilmaz S, Günel JM, Carrión-Grant G, Yılmaz B, Grady C, Tanrıkulu B, Bakırcıoğlu M, Kaymakçalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilgüvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kılıç T, Lifton RP, Noonan JP, Yasuno K, Günel M. Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013, 339: 1077-1080. PMID: 23348505, PMCID: PMC4808587, DOI: 10.1126/science.1233009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrain NeoplasmsChromosomes, Human, Pair 22DNA Mutational AnalysisFemaleGenes, Neurofibromatosis 2Genomic InstabilityGenomicsHumansKruppel-Like Factor 4Kruppel-Like Transcription FactorsMaleMeningeal NeoplasmsMeningiomaMiddle AgedMutationNeoplasm GradingProto-Oncogene Proteins c-aktReceptors, G-Protein-CoupledSmoothened ReceptorTumor Necrosis Factor Receptor-Associated Peptides and ProteinsHealth System, Community-Based, or Usual Dementia Care for Persons With Dementia and Caregivers
Reuben D, Gill T, Stevens A, Williamson J, Volpi E, Lichtenstein M, Jennings L, Galloway R, Summapund J, Araujo K, Bass D, Weitzman L, Tan Z, Evertson L, Yang M, Currie K, Green A, Godoy S, Abraham S, Reese J, Samper-Ternent R, Hirst R, Borek P, Charpentier P, Meng C, Dziura J, Xu Y, Skokos E, He Z, Aiudi S, Peduzzi P, Greene E, Serrano K, Unger E, Arruda L, Bautista L, Callahan C, Maslow K, Ling S, Bonner A, Pace D, Cherry D, Kremer I, Nicholson B, Stephens C, Hendler R, Carnie M, Shelton A, Mignosa B, Funaro B, Eisenmann K, Lu C, Chattopadhyay S, Rhoades D, Lakomski A, Maher D, McCurry D, Williamson S, Moyer S, Robertson L, Tilles A, Battle L, Walker W, Levine S, Knight G, Eaton A, Rose T, Weston E, Orr B, Lang S, Rinaldi S, Shore J, Garboczi L, Phoenix K, Mitchell M, Levan L, Layza M, Musgrave D, Silverman J, Martin A, Nienstedt J, Handoo R, Woolard N, Burcombe D, Hutchens C, Sanghi S, Ocloo A, Essiet S, Shah M, Bartosh H, Banda J, Birchfield T, Roznos T, Collins B, Parker D, Matlock M, Drew L, Jones T, Hill B, Walker J, Wills J, Andrews M, Kroloff S, Brown G, Franz C, Perez G, Castillo E, Flores C, Raji M, Martinez E, Skinkis P, Williams A, Minello S, Sherrod J, Odejimi A, Lockhart M, McDonald A, Gibson D, Tobias N, Spetter K, Finney G, Ladd I, Weaver K, Nicoletto P, Smith D, DeLucca R, Delmar N, Dopko J, Patel M, Berry P, Zimmerman K, Fasciana J, Hendricks L, Freedman K, Gudonis S, Drutarovsky H, Gurzynski A, Shillabeer M, Shipsky K, Cannon C, Rahm A, Sharf L, Kearney K, Liu J, Keeler E, Ruder T. Health System, Community-Based, or Usual Dementia Care for Persons With Dementia and Caregivers. JAMA 2025, 333: 950-961. PMID: 39878968, PMCID: PMC11780506, DOI: 10.1001/jama.2024.25056.Peer-Reviewed Original ResearchConceptsCommunity-based careModified Caregiver Strain IndexHealth system-basedCaregiver Strain IndexCaregiver self-efficacyUsual careDementia careHealth systemCommunity-basedNPI-QPrimary outcomeApproaches to dementia careCommunity-based dementia careCommunity-based care interventionsSelf-efficacyDementia care programDementia care specialistsSecondary outcomesStrain indexSystem-based careCommunity-dwelling personsNeuropsychiatric Inventory QuestionnairePatient behavioral symptomsNPI-Q scoresCaregiver outcomesSafety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Nassar A, Alaiwi S, Zarif T, Denu R, Macaron W, Abdel-Wahab N, Freeman D, Vasbinder A, Hayeck S, Anderson E, Goodman R, Johnson D, Grynberg S, Shapira R, Kwan J, Woodford R, Long G, Haykal T, Dent S, Kojima Y, Yonemor K, Tandon A, Trevino A, Akhter N, Yang E, Hui G, Drakaki A, El-Am E, Kozaily E, Al-Hader A, Farhat E, Babu P, Mittra A, Li M, Jones N, Baena J, Herrera M, Foderaro S, Nana F, Kim C, Sackstein P, Parikh K, Desai A, Smith C, Cortellini A, Pinato D, Korolewicz J, Lopetegui-Lia N, Funchain P, Choudhary A, Asnani A, Navani V, Meyers D, Stukalin I, Gallegos J, Trent J, Nusrat S, Malvar C, McKay R, Neilan T, Choueiri T, Naqash A. Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study. Journal For ImmunoTherapy Of Cancer 2025, 13: e009364. PMID: 40032601, PMCID: PMC11877189, DOI: 10.1136/jitc-2024-009364.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitor initiationImmune checkpoint inhibitorsTreatment-related adverse eventsObjective response rateProgression-free survivalCardiac metastasisOverall survivalRetrospective studyAnti-cytotoxic T-lymphocyte antigen 4Dose of immune checkpoint inhibitorsEfficacy of immune checkpoint therapyAnti-programmed death-1International multicenter retrospective studyMulticenter international retrospective studyT-lymphocyte antigen-4Non-small cell lung cancerMedian follow-up timeClinical outcomes of patientsICI-based regimensMultiple cardiac metastasesSolid Tumors V.1.1Immune checkpoint therapyResponse Evaluation CriteriaInternational retrospective studyMulticenter retrospective studySeverity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus
Bajema K, Bui D, Yan L, Li Y, Rajeevan N, Vergun R, Berry K, Huang Y, Lin H, Aslan M, Ioannou G. Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus. JAMA Internal Medicine 2025, 185: 324-334. PMID: 39869355, PMCID: PMC11773409, DOI: 10.1001/jamainternmed.2024.7452.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusLong-term mortalitySARS-CoV-2Syncytial virusCohort studyAssociated with higher long-term mortalityRisk differenceIntensive care unit admissionSeasonal influenza vaccineRetrospective cohort studyDisease severity of COVID-19Long-term deathAssociated with more severe disease outcomesRisk of deathCompare disease severitySevere disease outcomesRisk of hospitalizationSeverity of COVID-19Same-day testingInfluenza vaccineInverse probability weightingUnit admissionCumulative incidenceMortality of COVID-19Primary outcomeImplementation of Brief Submaximal Cardiopulmonary Testing in a High-Volume Presurgical Evaluation Clinic: Feasibility Cohort Study
Carr Z, Agarkov D, Li J, Charchaflieh J, Brenes-Bastos A, Freund J, Zafar J, Schonberger R, Heerdt P. Implementation of Brief Submaximal Cardiopulmonary Testing in a High-Volume Presurgical Evaluation Clinic: Feasibility Cohort Study. JMIR Perioperative Medicine 2025, 8: e65805. PMID: 39773953, PMCID: PMC11888076, DOI: 10.2196/65805.Peer-Reviewed Original ResearchConceptsDuke Activity Status IndexPeak oxygen uptakePeak METsEvaluation clinicParticipant satisfactionOxygen uptakeSubmaximal cardiopulmonary exercise testingFunctional capacity assessmentLow functional capacityCardiopulmonary exercise testingPerceived exertionMET assessmentStructured surveyCapacity surveyMedian patient satisfactionProvider-drivenExercise testMean session timePearson correlation coefficientSurvey scoresCardiopulmonary testFunctional capacityPatient satisfactionCohort studyInclusion criteriaArtificial intelligence-guided detection of under-recognised cardiomyopathies on point-of-care cardiac ultrasonography: a multicentre study
Oikonomou E, Vaid A, Holste G, Coppi A, McNamara R, Baloescu C, Krumholz H, Wang Z, Apakama D, Nadkarni G, Khera R. Artificial intelligence-guided detection of under-recognised cardiomyopathies on point-of-care cardiac ultrasonography: a multicentre study. The Lancet Digital Health 2025, 7: e113-e123. PMID: 39890242, DOI: 10.1016/s2589-7500(24)00249-8.Peer-Reviewed Original ResearchConceptsYale New Haven Health SystemPoint-of-care ultrasonographyMount Sinai Health SystemTransthyretin amyloid cardiomyopathyArtificial intelligenceHealth systemAmyloid cardiomyopathyHypertrophic cardiomyopathyRetrospective cohort of individualsCardiomyopathy casesTesting artificial intelligenceConvolutional neural networkSinai Health SystemCohort of individualsOpportunistic screeningHypertrophic cardiomyopathy casesMulti-labelPositive screenAI frameworkEmergency departmentMortality riskNeural networkLoss functionCardiac ultrasonographyAugmentation approachProspective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma
Biswas D, Liu Y, Herrero J, Wu Y, Moore D, Karasaki T, Grigoriadis K, Lu W, Veeriah S, Naceur-Lombardelli C, Magno N, Ward S, Frankell A, Hill M, Colliver E, de Carné Trécesson S, East P, Malhi A, Snell D, O’Neill O, Leonce D, Mattsson J, Lindberg A, Micke P, Moldvay J, Megyesfalvi Z, Dome B, Fillinger J, Nicod J, Downward J, Szallasi Z, Hackshaw A, Jamal-Hanjani M, Kanu N, Birkbak N, Swanton C. Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma. Nature Cancer 2025, 6: 86-101. PMID: 39789179, PMCID: PMC11779643, DOI: 10.1038/s43018-024-00883-1.Peer-Reviewed Original ResearchConceptsLung adenocarcinomaStage I diseaseClinicopathological risk factorsSurvival of patientsResponse to treatmentRNA sequencing dataI diseaseSequence dataMetastatic clonesNeedle biopsyIndividual tumorsLung expressionTranscription signalsPrognostic informationWhole exomeExpressed genesChemotherapy sensitivityProspective validationSurvival associationsTranscriptomic heterogeneityHuman tumorsEvolutionary measuresChromosomal instabilityRisk factorsNatural historyThe Association Between Cost-Related Insulin Rationing and Health Care Utilization in U.S. Adults With Diabetes.
Borden C, Bakkila B, Nally L, Lipska K. The Association Between Cost-Related Insulin Rationing and Health Care Utilization in U.S. Adults With Diabetes. Diabetes Care 2025, 48: 400-404. PMID: 39746142, PMCID: PMC11870294, DOI: 10.2337/dc24-2117.Peer-Reviewed Original ResearchConceptsHealth care utilizationUrgent care visitsCare utilizationCare visitsU.S. adultsAssociated with health care utilizationNational Health Interview Survey respondentsAssociated with higher health care utilizationEmergency departmentHigher health care utilizationOdds of ED visitsRationing of health careCross-sectional studyNegative binomial regression modelsZero-inflated negative binomial regression modelsBinomial regression modelsHealth careED visitsSurvey weightsAge-stratifiedLogistic regressionSurvey respondentsVisitsRegression modelsAdultsEffectiveness of dolutegravir-based regimens compared to raltegravir-, elvitegravir-, bictegravir, and darunavir-based regimens among older adults with HIV in the Veterans Aging Cohort Study (VACS)
Yan L, Henegar C, Marconi V, Gordon K, Hicks C, Vannappagari V, Justice A, Aslan M. Effectiveness of dolutegravir-based regimens compared to raltegravir-, elvitegravir-, bictegravir, and darunavir-based regimens among older adults with HIV in the Veterans Aging Cohort Study (VACS). AIDS Research And Therapy 2024, 21: 96. PMID: 39709467, PMCID: PMC11662819, DOI: 10.1186/s12981-024-00681-w.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmidesAnti-HIV AgentsCohort StudiesDarunavirDrug Therapy, CombinationFemaleHeterocyclic Compounds, 3-RingHeterocyclic Compounds, 4 or More RingsHIV InfectionsHIV Integrase InhibitorsHumansMaleMiddle AgedOxazinesPiperazinesPyridazinesPyridonesQuinolonesRaltegravir PotassiumTreatment OutcomeVeteransViral LoadConceptsVeterans Aging Cohort StudyRAL-based regimenAntiretroviral therapyAging Cohort StudyCohort studyOdds of virologic suppressionIntegrase strand transfer inhibitorsDarunavir-based regimensDolutegravir-based regimensDTG-based regimensAntiretroviral therapy experienceHuman immunodeficiency virusDTG-based regimenInverse probability of treatment weightingStrand transfer inhibitorsBackgroundReal-world dataProbability of treatment weightingMethodsThis cohort studyVirologic suppressionVirological failureVirological effectImmunodeficiency virusDarunavir/ritonavirClinical outcomesRegimen initiationUS Tobacco 21 Policies and Potential Mortality Reductions by State
Tam J, Crippen A, Friedman A, Jeon J, Colston D, Fleischer N, Vander Woude C, Boelter M, Holford T, Levy D, Meza R. US Tobacco 21 Policies and Potential Mortality Reductions by State. JAMA Health Forum 2024, 5: e244445. PMID: 39705045, PMCID: PMC11662258, DOI: 10.1001/jamahealthforum.2024.4445.Peer-Reviewed Original ResearchConceptsPotential mortality reductionT21 policiesMortality reductionPremature deathEstimate smoking-attributable deathsLife yearsT21 lawsSmoking-attributable deathsTobacco-21 policiesPremature mortality reductionQuasi-experimental studyPolicy coverageState-specific dataDistrict of ColumbiaMortality rateTobacco 21Smoking cessationMain OutcomesSmoking initiationBirth cohortTobacco productsSmoking behaviorStatewide implementationCigarette policiesSmokingCharting the metabolic biogeography of the colorectum in cancer: challenging the right sided versus left sided classification
Jain A, Morris M, Berardi D, Arora T, Domingo-Almenara X, Paty P, Rattray N, Kerekes D, Lu L, Khan S, Johnson C. Charting the metabolic biogeography of the colorectum in cancer: challenging the right sided versus left sided classification. Molecular Cancer 2024, 23: 211. PMID: 39342363, PMCID: PMC11438248, DOI: 10.1186/s12943-024-02133-5.Peer-Reviewed Original ResearchConceptsRectal cancerNormal mucosaMetabolite abundancePatient-matched tumorTumor-specific metabolitesMetabolic heterogeneityPatient survivalRectosigmoid colonSigmoid colonAnatomic subsitePatient-matched normal mucosaTransverse colonMetabolomic profilesAscending colonCRC biomarkersMetabolome DatabaseDescending colonMetabolite changesLeft-sidedRight-sidedColorectumRisk factorsMetabolome mapCancerTumorPhase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes
Sundar R, Chia D, Zhao J, Lee A, Kim G, Tan H, Pang A, Shabbir A, Willaert W, Ma H, Huang K, Hagihara T, Tan A, Ong C, Wong J, Seo C, Walsh R, Chan G, Cheo S, Soh C, Callebout E, Geboes K, Ng M, Lum J, Leow W, Selvarajan S, Hoorens A, Ang W, Pang H, Tan P, Yong W, Chia C, Ceelen W, So J. Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes. ESMO Open 2024, 9: 103681. PMID: 39288528, PMCID: PMC11421236, DOI: 10.1016/j.esmoop.2024.103681.Peer-Reviewed Original ResearchConceptsGastric cancer peritoneal metastasisPeritoneal cancer indexNivolumab combinationPeritoneal metastasisPeritoneal tumorsNaive CD8+ T cellsCD8+ central memoryEnhanced T cell infiltrationTreatment-related adverse eventsCD8+ T cellsGrade 4 vomitingRegression grade 1First-in-human trialImmune checkpoint inhibitionMemory CD4+T cell infiltrationImmunogenic cell deathSystemic immunotherapyCheckpoint inhibitionSystemic therapyCancer indexCD4+Intraperitoneal treatmentT cellsAdverse events
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply